AAHI-SC2 Vaccine / ImmunityBio - LARVOL DELTA

THEMBA II T-Cell Vaccine: Vaccination With saRNA COVID-19 Vaccines (clinicaltrials.gov) - P1/2 | N=60 | Terminated | Sponsor: ImmunityBio, Inc. | N=180 ➔ 60 | Trial completion date: Sep 2023 ➔ Mar 2024 | Recruiting ➔ Terminated | Trial primary completion date: Sep 2023 ➔ Mar 2024; Discontinued prior to enroll in Phase 2

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Infectious Disease • Novel Coronavirus Disease

THEMBA II T-Cell Vaccine: Vaccination With saRNA COVID-19 Vaccines (clinicaltrials.gov) - P1/2 | N=180 | Recruiting | Sponsor: ImmunityBio, Inc. | Trial completion date: Jun 2023 ➔ Sep 2023 | Trial primary completion date: Jun 2023 ➔ Sep 2023

Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

Heterologous saRNA Prime, DNA Dual-Antigen Boost SARS-CoV-2 Vaccination Elicits Robust Cellular Immunogenicity and Cross-Variant Neutralizing Antibodies. (PubMed, Front Immunol) - "The S sequence in the AAHI-SC2 vaccine comprises the D614G mutation, two prolines to stabilize S in the prefusion conformation, and 3 glutamines in the furin cleavage region to confer protease resistance...Sera from mice receiving AAHI-SC2 homologous or heterologous vaccination were found to be highly neutralizing for all pseudovirus strains tested: Wuhan, Beta, Delta, and Omicron strains. The findings here, taken in consideration with the availability of both vaccines in thermostable formulations, support the testing of heterologous vaccination by an AAHI-SC2 > AdS+N regimen in animal models of SARS-CoV-2 infection to assess its potential to provide increased protection against emerging SARS-CoV-2 variants particularly in regions of the world where the need for cold-chain storage has limited the distribution of other vaccines."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD4 • CD8

THEMBA II T-Cell Vaccine: Vaccination With saRNA COVID-19 Vaccines (clinicaltrials.gov) - P1/2 | N=180 | Recruiting | Sponsor: ImmunityBio, Inc.

New P1/2 trial • Infectious Disease • Novel Coronavirus Disease